Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. manufactures automated insulin delivery systems for the management of type 1 and type 2 diabetes mellitus. The company's primary product portfolio includes the Tandem Mobi system—a wearable insulin pump controllable via compatible Android smartphones—and the t:slim X2 insulin pump featuring a color touchscreen interface and multiple continuous glucose monitor (CGM) compatibility options. Both systems are powered by Control-IQ+ technology, a predictive algorithm with AutoBolus capability designed to prevent hyperglycemic and hypoglycemic episodes. Control-IQ+ is indicated for type 1 diabetes in persons 2 years and older and type 2 diabetes in persons 18 years and older. Tandem also manufactures infusion sets in various cannula materials and tubing configurations to support their pump systems. The company provides remote software update capability, mobile and cloud-based diabetes management applications, 24/7 customer support, personalized pump training, and limited warranty coverage. All insulin pumps are FDA-cleared subcutaneous delivery devices requiring a prescription (RX Only). The company serves patients requiring insulin therapy across the United States and maintains regulatory compliance with FDA premarket clearance requirements for medical devices.